The STAR*D trial: Revealing the need for better treatments

Psychiatric Services

Volumn 60, Issue 11, 2009, Pages 1466-1467

  Insel, Thomas R ^a   Wang, Philip S ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; KETAMINE; SEROTONIN UPTAKE INHIBITOR;

BRAIN DEPTH STIMULATION; COGNITIVE THERAPY; DEPRESSION; MAJOR DEPRESSION; MENTAL HEALTH CARE; OBSESSIVE COMPULSIVE DISORDER; REMISSION; SHORT SURVEY; TRANSCRANIAL MAGNETIC STIMULATION; TREATMENT RESPONSE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; MULTICENTER STUDY; PERSONALIZED MEDICINE; RANDOMIZED CONTROLLED TRIAL; TREATMENT FAILURE; TREATMENT OUTCOME;

DEPRESSIVE DISORDER, MAJOR; HUMANS; INDIVIDUALIZED MEDICINE; REMISSION INDUCTION; SEROTONIN UPTAKE INHIBITORS; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 85047684623     PISSN: 10752730     EISSN: 15579700     Source Type: Journal    
DOI: 10.1176/ps.2009.60.11.1466     Document Type: Short Survey

References (12)

1. The World Health Report, 2002: Reducing Risks, Promoting Healthy Life. Geneva, World Health Organization, 2002
2. Kessler RC, Berglund P, Demler O, et al: The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 289:3095-3105, 2003 (Pubitemid 37432885)
3. Wang PS, Lane M, Olfson M, et al: Twelve-month use of mental health services in the United States: results from the National Comorbidity Survey Replication. Archives of General Psychiatry 62:629-640, 2005 (Pubitemid 40973438)
4. Kessler RC, Berglund P, Borges G, et al: Trends in suicide ideation, plans, gestures, and attempts in the United States, 1990-1992 to 2001-2003. JAMA 293:2487-2495, 2005
5. Kessler RC, Demler O, Frank RG, et al: Prevalence and treatment of mental disorders, 1990 to 2003. New England Journal of Medicine 352:2515-2523, 2005
6. US prescription sales grew 3.8 percent in 2007, to $286.5 billion. Norwalk, Conn, IMS, 2008. Available at www.imshealth.com
7. Zarate CA Jr, Singh JB, Carlson PJ, et al: A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Archives of General Psychiatry 63:856-864, 2006
8. McMahon FJ, Buervenich S, Charney D, et al: Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment. American Journal of Human Genetics 78:804-814, 2006
9. Laje G, Paddock S, Manji H, et al: Genetic markers of suicidal ideation emerging during citalopram treatment of major depression. American Journal of Psychiatry 164:1530-1538, 2007 (Pubitemid 350069732)
10. Perlis RH, Patrick A, Smoller JW, et al: When is pharmacogenetic testing for antidepressant response ready for the clinic? A cost-effectiveness analysis based on data from the STAR*D study. Neuropsychopharmacology, in press
11. Salvadore G, Cornwell BR, Colon-Rosario V, et al: Increased anterior cingulate cortical activity in response to fearful faces: a neurophysiological biomarker that predicts rapid antidepressant response to ketamine. Biological Psychiatry 65:289-295, 2009
12. Mayberg HS, Lozano AM, Voon V, et al: Deep brain stimulation for treatment-resistant depression. Neuron 45:651-660, 2005 (Pubitemid 40320700)